Man Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Man Group’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-139,944	Closed	-$3.02M	–	2386
2025 Q4	$3.02M	Buy	139,944 +105,684	+308%	+$2.05M	0.01%	1292
2025 Q3	$523K	Sell	34,260 -23,671	-41%	-$308K	﹤0.01%	1846
2025 Q2	$513K	Buy	57,931 +29,149	+101%	+$256K	﹤0.01%	1827
2025 Q1	$225K	Buy	+28,782	New	+$241K	﹤0.01%	2003

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Man Group's AVDL Position: Q1 2026 in Review

Man Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 139,944 shares — an estimated $3.02M sold.

Man Group first reported a position in AVDL in Q1 2025 and held it in 4 quarters. The position peaked at $3.02M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Man Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Man Group sold 139,944 Avadel Pharmaceuticals shares in Q1 2026, an estimated $3.02M.
Man Group first reported a position in Avadel Pharmaceuticals in Q1 2025 and held it in 4 quarters.
Man Group's Avadel Pharmaceuticals position peaked at $3.02M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.